VEGFA and age-related macular degeneration: Entities with a significant pro-angiogenic component, such as exudative AMD, may respond to anti-VEGF agents, while those with a broad inflammatory component, such as uveitic CME or Irvine-Gass syndrome, may respond better to anti-inflammatory drugs [12].